Technical Analysis for CGEM - Cullinan Management, Inc.

Grade Last Price % Change Price Change
F 27.48 -3.61% -1.03
CGEM closed down 3.61 percent on Wednesday, June 16, 2021, on 70 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical CGEM trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Stochastic Reached Oversold Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 20 DMA Bearish -3.61%
MACD Bearish Centerline Cross Bearish -3.61%
Multiple of Ten Bearish Other -3.61%
Down 3 Days in a Row Weakness -3.61%
Older End-of-Day Signals for CGEM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Lower Bollinger Band about 4 hours ago
Lower Bollinger Band Support about 4 hours ago
Down 5% about 4 hours ago
Down 3% about 5 hours ago
Down 2 % about 6 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cullinan Management, Inc. Description

Cullinan Oncology, LLC, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. The company's preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell acute lymphoblastic leukemia; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. It has a collaboration agreement with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, LLC was founded in 2016 and is headquartered in Cambridge, Massachusetts.


Sector: Other
Industry: Other
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Solid Tumors Immune System Antibodies Oncology Monoclonal Antibody Cancer Immunotherapy Non Small Cell Lung Cancer Acute Myeloid Leukemia Tumors Cell Therapy Therapies For Cancer Treatment Of Acute Myeloid Leukemia Oncology Therapies B Cell Acute Lymphoblastic Leukemia Preclinical Products

Is CGEM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 59.85
52 Week Low 26.57
Average Volume 216,234
200-Day Moving Average 0.00
50-Day Moving Average 31.21
20-Day Moving Average 30.34
10-Day Moving Average 31.31
Average True Range 2.43
ADX 15.28
+DI 22.56
-DI 27.44
Chandelier Exit (Long, 3 ATRs) 30.36
Chandelier Exit (Short, 3 ATRs) 33.87
Upper Bollinger Bands 34.23
Lower Bollinger Band 26.45
Percent B (%b) 0.13
BandWidth 25.64
MACD Line -0.38
MACD Signal Line -0.24
MACD Histogram -0.1475
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.29
Resistance 3 (R3) 31.45 30.35 30.66
Resistance 2 (R2) 30.35 29.38 30.27 30.44
Resistance 1 (R1) 28.91 28.78 28.36 28.75 30.23
Pivot Point 27.81 27.81 27.53 27.73 27.81
Support 1 (S1) 26.37 26.84 25.82 26.21 24.73
Support 2 (S2) 25.27 26.24 25.19 24.52
Support 3 (S3) 23.83 25.27 24.31
Support 4 (S4) 23.67